Physician profile
Susan P Detwiler
NPI 1184656290
$7,079.55
in general payments reported to CMS, 2019-2025
25 companies · $2,635 in 2025
The $2,635 reported for 2025 was more than what 91% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $15.81 · 2021: $461 · 2022: $491 · 2023: $1,330 · 2024: $1,684 · 2025: $2,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,454 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,454.39 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,314.47 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $776.95 | 2019-2025 | Tremfya, Remicade, Stelara |
| Genzyme Corporation | $535.44 | 2019-2025 | |
| Incyte Corporation | $497.21 | 2022-2025 | Opzelura |
| Pfizer INC. | $430.60 | 2019-2025 | |
| Ucb, INC. | $414.25 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $413.17 | 2019-2025 | Ilumya |
| Janssen Scientific Affairs, LLC | $378.40 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $337.81 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $330.59 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $255.96 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $225.56 | 2023-2024 | Vtama |
| Amgen INC. | $202.65 | 2019-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $164.28 | 2023-2025 | Zoryve |
| Regeneron Pharmaceuticals, INC. | $149.00 | 2025 | Libtayo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $131.35 | 2023-2025 | Dupixent, Libtayo |
| Strata Skin Sciences, INC. | $118.86 | 2024 | Xtrac |
| Biofrontera INC. | $89.37 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $88.50 | 2021-2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.28 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $69.48 | 2022-2025 | Aklief |
| Dusa Pharmaceuticals, INC. | $24.06 | 2019 | |
| Journey Medical Corporation | $23.12 | 2023 | |
| Revance Therapeutics, INC. | $19.50 | 2024 | Daxxify |
| Organon LLC | $13.69 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Detwiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.